Market Newsdesk

Booz Allen Celebrates Albedo’s Historic Clarity-1 Launch

The first Very Low Earth Orbit (VLEO) satellite marks significant milestone in commercial space innovation

MCLEAN, Va.–(BUSINESS WIRE)–Booz Allen Hamilton (NYSE: BAH) today announced that Booz Allen Ventures portfolio company Albedo has successfully launched Clarity-1, the first commercial satellite to operate in Very Low Earth Orbit (VLEO), marking a significant milestone in commercial space innovation. This achievement comes just over a year after Booz Allen Ventures’ strategic investment in Albedo, demonstrating the rapid acceleration of developing commercial technology to meet critical government needs.

With Clarity-1 now on orbit, Albedo has introduced a breakthrough capability—10 cm visible and 2-meter thermal imagery from VLEO—delivering resolutions previously limited to aircraft and drones. This will further enhance capabilities for Earth observation and national security use cases across government and industry.

“Albedo’s rapid trajectory from investment to launch demonstrates the speed to outcomes that is critical for national security. We are excited to actively bring these capabilities to the U.S. government,” said Brian MacCarthy, managing director of Booz Allen Ventures. “This milestone showcases Booz Allen’s ability to anticipate, build, and invest in advanced technology that truly transforms missions.”

By leveraging VLEO’s unique advantages, Albedo is positioned to contribute to Space Domain Awareness and provide an alternate vantage point to traditional Earth observation methods. With its Strategic Funding Increase (STRATFI) contract from the Air Force Research Laboratory (AFRL), Albedo’s technology is already playing an important role in the U.S. government’s space strategy.

“The launch of Clarity-1 is a pivotal moment for the space industry,” said Chris Bogdan, executive vice president at Booz Allen and leader of the firm’s Space business. “The ability to collect ultra-high-resolution data at a fraction of the cost and timeline of traditional satellites is a transformational shift in space technology. This launch not only showcases Albedo’s ingenuity but also highlights the power of dual-use commercial technology to meet mission-critical needs.”

“Ultra-high-resolution data will be essential for delivering the necessary intelligence and analytics to inform our nation’s decision-making,” said Winston Tri, co-founder and CPO at Albedo. “As Albedo accelerates its vision to provide unparalleled geospatial insights, we look forward to an ongoing partnership with Booz Allen.”

Booz Allen’s investment in Albedo is part of its broader venture capital strategy, which focuses on identifying, investing, and scaling emerging technologies that can rapidly drive mission outcomes for government clients. Through its corporate venture capital arm, Booz Allen has invested in 13 very promising startups to accelerate AI, cyber, and space innovation in support of national security.

As the leading provider of AI and cybersecurity to the federal government, Booz Allen is uniquely positioned to integrate emerging capabilities into the broader national security ecosystem. Booz Allen is committed to advancing the future of space technology by bridging the gap between commercial innovation and government missions.

About Booz Allen Hamilton

Booz Allen is the advanced technology company delivering outcomes with speed for America’s most critical defense, civil, and national security priorities. We build technology solutions using AI, cyber, and other cutting- edge technologies to advance and protect the nation and its citizens. By focusing on outcomes, we enable our people, clients, and their missions to succeed—accelerating the nation to realize our purpose: Empower People to Change the World®.

With global headquarters in McLean, Virginia, our firm employs approximately 35,900 people globally as of December 31, 2024, and had revenue of $10.7 billion for the 12 months ended March 31, 2024. To learn more, visit www.boozallen.com. (NYSE: BAH)

Forward-Looking Statements

Certain statements contained in this release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include statements that do not directly relate to any historical or current fact. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “could,” “should,” “forecasts,” “expects,” “intends,” “plans,” “anticipates,” “projects,” “outlook,” “believes,” “estimates,” “predicts,” “potential,” “continue,” “preliminary,” or the negative of these terms or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to have been correct.

These forward-looking statements relate to future events or future financial performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. A number of important factors could cause actual results to differ materially from those contained in or implied by these forward-looking statements, including those factors discussed in Booz Allen’s filings with the Securities and Exchange Commission (SEC), including Booz Allen’s Annual Report on Form 10-K for the fiscal year ended March 31, 2024 and other filings and reports that may be filed from time to time with the SEC, which can be found at the SEC’s website at www.sec.gov. All forward-looking statements attributable to Booz Allen or persons acting on Booz Allen’s behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

BAHPR-CO

View source version on businesswire.com: https://www.businesswire.com/news/home/20250319744886/en/

Media Relations: Amanda Allison, [email protected]

Investor Relations: [email protected]

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Other Defense Contracts Technology White House/Federal Government Defense Other Policy Issues Security Satellite Photography Government Technology Aerospace Public Policy/Government Manufacturing

MEDIA:

Logo

UiPath Offers Complimentary Trial of Automation Cloud Public Sector to Assist U.S. Government Agencies’ Efficiency Initiatives

NEW YORK–(BUSINESS WIRE)–
UiPath (NYSE: PATH), a leading enterprise automation and AI software company, today announced a comprehensive Automation Cloud™ Public Sector free trial designed to help government agencies address operational challenges and drive productivity improvements.

Public sector organizations have specific requirements that demand robust, secure, and compliant software solutions. Automation Cloud Public Sector is a cloud-based solution tailored to the specific requirements of public sector organizations in the United States that enables measurable efficiency gains.

“In an era of rapidly changing policy mandates and increasing efficiency requirements, automation has moved beyond a strategic priority to become a necessity,” said Chris Radich, Public Sector Chief Technology Officer at UiPath. “Government agencies handle vast amounts of sensitive data, from citizen records to financial transactions, making data security and privacy paramount. UiPath is a proud strategic partner of public sector organizations and has years of experience building Automation Centers of Excellence. These initiatives have systematically eliminated millions of hours of repetitive work, which saves taxpayer money and allows talented public servants to focus on mission-critical initiatives that directly serve the American people.”

UiPath Automation Cloud Public Sector holds FedRAMP Moderate compliance, adhering to the rigorous security controls mandated by the Federal Risk and Authorization Management Program. This authorization offers public sector agencies a viable and secure method to achieve aggressive efficiency mandates.

The 60-day free trial of Automation Cloud Public Sector provides government leaders in federal, state, or local agencies with access to critical automation solutions such as process mining, AI-powered Document Understanding, unattended and attended robots, low-code apps, and other capabilities. It offers a pragmatic solution to:

• decrease administrative costs
• improve spend management and transparency
• accelerate document processing with out of the box M/L models
• demonstrate tangible operational improvements

“Government agencies require practical, implementable solutions to meet evolving operational demands. Our trial provides a direct pathway to measurable efficiency gains,” said Dave Melvin, Vice President of Public Sector at UiPath.

Government agencies can visit here to contact UiPath to enroll in the Automation Cloud Public Sector free trial.

In addition, register here for the UiPath on Tour Agentic Automation Summit in Washington, D.C. on April 29. The annual summit, titled “Ushering in the Era of Efficiency”, will feature prominent government leaders discussing how they are transforming their agencies with agents, robots, and people.

About UiPath

UiPath (NYSE: PATH) develops AI technology that mirrors human intelligence with ever-increasing sophistication, transforming how businesses operate, innovate, and compete. The UiPath Platform™ accelerates the shift toward a new era of agentic automation—one where agents, robots, people, and models integrate seamlessly to enable autonomous processes and smarter decision making. With a focus on security, accuracy, and resiliency, UiPath is committed to shaping a world where AI enhances human potential and revolutionizes industries. For more information, visit www.uipath.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250319849671/en/

UiPath Media Contact

UiPath

[email protected]

UiPath Investor Relations Contact

UiPath

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Software Professional Services Robotics Data Management White House/Federal Government Apps/Applications Technology State/Local Artificial Intelligence Security Other Professional Services Public Policy/Government

MEDIA:

Logo

AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

LATHAM, N.Y.–(BUSINESS WIRE)–
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market open on Wednesday, April 2, 2025, followed by a virtual cardiovascular investor event, offering a deeper dive into the company’s cardiovascular business and products.

Fiscal 2025 Third Quarter Financial Results Conference Call

The Company’s management will host a conference call at 8:00 am ET the same day to discuss the results.

To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international).

This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available, until Wednesday, April 09, 2025 at 11:59 PM ET. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13752371.

Virtual Cardiovascular Investor Event

AngioDynamics will host a virtual investor event on April 2, 2025 at 9:00am to provide investors a deeper dive into the cardiovascular technology portfolio and strategic vision.

The event will be webcast and can be accessed through the “Investors” section of the AngioDynamics website at www.angiodynamics.com.

About AngioDynamics, Inc.

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.

The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250319101713/en/

Investors:

AngioDynamics, Inc.

Stephen Trowbridge, Executive Vice President & CFO

(518) 795-1408

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Research Medical Devices Health Technology Cardiology Other Health Health Other Science Science Oncology

MEDIA:

Posted on March 19, 2025 8:03 am

MetLife Xcelerator Hits 4.5 Million Active Consumers and Surpasses $200M in Premiums

MetLife Xcelerator Hits 4.5 Million Active Consumers and Surpasses $200M in Premiums

• MetLife Xcelerator evolves and transforms into a business unit to transform embedded insurance in the region.
• Driving insurance inclusion through disruptive technology, strategic partnerships, and a fully digital access model as part of MetLife’s New Frontier strategy.

NEW YORK–(BUSINESS WIRE)–MetLife, a global leader in insurance solutions, announces the creation of a new regional business unit in Latin America by the name of MetLife Xcelerator, marking a significant milestone in the evolution of the MetLife Xcelerator platform and execution of the company’s New Frontier strategy. Designed to lead the transformation of embedded insurance and democratize access to financial protection, the MetLife Xcelerator platform, launched in November 2023, is redefining the insurance ecosystem by using advanced technology and an agile model to connect millions of people to more accessible, personalized insurance solutions.

Under the leadership of Javier Cabello, recently appointed as head of MetLife Xcelerator in Latin America, this dedicated business unit—supported by a multidisciplinary team of experts in technology, data, customer experience, marketing, and product development—is enabling the agile delivery of scalable solutions that reduce time-to-market and address the dynamic demands of partners and consumers across the region.

A New Model for an Evolving Market

As highlighted during MetLife’s Investor Day in December 2024, MetLife Xcelerator is a cornerstone of the New Frontier strategy, which emphasizes distribution innovation as a key enabler for future growth. With an innovative approach rooted in the B4B2C (Business-for-Business-to-Consumer) model, Xcelerator enhances the value proposition of strategic partners such as digital banks, e-wallets, e-commerce platforms, retailers, and traditional financial institutions. By seamlessly integrating insurance solutions into partners’ products and services, Xcelerator creates fully digital and customized experiences for end users.

“MetLife Xcelerator is a unique, innovative platform that operates with the speed and agility of a startup while leveraging MetLife’s global scale and expertise,” commented Naomi Johnson, MetLife Latin America’s Head of Strategy and Transformation. “We made investments in technology and the team to innovate at speed, ensuring seamless integration for our partners and creating a new standard for embedded insurance in the region.”

MetLife Xcelerator boosts customer loyalty and satisfaction by providing a best-in-class customer experience while offering business partners a competitive edge through a simple, flexible, and fully customizable integration of embedded insurance solutions into their offerings. As Eric Clurfain, MetLife Latin America’s Regional President, noted, “MetLife Xcelerator accelerated our growth in Brazil, and we’re now very excited to deploy and scale these capabilities across the region and beyond.”

A Commitment to Insurance Democratization

At a time when technology and strategic partnerships are reshaping the global insurance market, MetLife Xcelerator stands out as a key enabler of financial and insurance inclusion in Latin America. The unit exemplifies MetLife’s dedication to building digital ecosystems that make insurance accessible to all, regardless of geographic or socioeconomic barriers.

Since its launch just over a year ago, MetLife Xcelerator has achieved significant results, with operations live in Mexico, Brazil, and Chile with over 4.5 million in-force customers, and more than $200 million in PFOs (Premiums, Fees, and Other income). Looking ahead, Xcelerator is poised to capture value in rapidly emerging markets such as retailers, telecommunications companies, and digital marketplaces while deepening its presence in core financial services partnerships.

With the New Frontier strategy as its foundation, MetLife Xcelerator represents not only a growth engine for the company and its partners but also a powerful example of how innovation can close financial protection gaps and drive equitable outcomes in a region with tremendous growth potential. “We are redefining how people access insurance,” said Cabello. “With a fully digital approach that is faster, more accessible, and personalized, we are bringing financial protection to millions of people and setting a new standard for embedded insurance in the region.”

To learn more about MetLife Xcelerator, visit https://www.metlife.com/us/lp/xcelerator-es/

About MetLife

MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Asia, Latin America, Europe and the Middle East.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250319048870/en/

For media in the U.S. and LatAm, please contact:

Santiago Airasca

VP, Communications LatAm

[email protected]

KEYWORDS: Latin America United States North America New York

INDUSTRY KEYWORDS: Professional Services Insurance Human Resources Finance

MEDIA:

Logo

Chamberlain University Appoints Mary Beth Kingston to its Board of Trustees

Mary Beth Kingston joins Chamberlain University’s Board of Trustees, bringing her visionary leadership and innovative approach to nursing to the nation’s largest nursing school.

CHICAGO–(BUSINESS WIRE)–Chamberlain University, an Adtalem Global Education (NYSE: ATGE) institution and largest nursing school in the country¹, has appointed Mary Beth Kingston, PhD, RN, FAAN, to its board of trustees as chair, effective immediately.

A 2024 recipient of the prestigious Lifetime Achievement Award from the American Organization for Nursing Leadership (AONL), Kingston brings more than 40 years of experience in the healthcare industry to Chamberlain University. A visionary leader in nursing, Mary Beth Kingston brings her innovative leadership, steadfast commitment to nurse safety, and strong advocacy for health equity and education to this role.

“Kingston’s exceptional leadership in nursing and unwavering dedication to nursing and health professions education makes her an invaluable addition to the Chamberlain University’s Board of Trustees,” said Karen Cox, PhD, RN, FACHE, FAAN, president, Chamberlain University. “Her firsthand experience as a leader in a major health system through the challenges of the pandemic and beyond provides unparalleled insights into the future of nursing and healthcare. As a trusted thought leader, she is shaping the industry’s next chapter and advancing the profession at a critical time.”

Before joining the Chamberlain Board of Trustees, Kingston served as Executive Vice President and Chief Nursing Officer for Advocate Health, overseeing the company’s nursing strategy and operations. She previously served on the Milwaukee Urban League and American Hospital Association board of trustees and chaired the Hospitals Against Violence Advisory Group. Currently, she sits on Providence Saint Joseph’s Health and Main Line Health boards. In addition to receiving the AONL Lifetime Achievement Award, Kingston served as the organization’s president in 2019. She was also named one of Modern Healthcare’s 50 Most Influential Clinical Executives in 2021, 2023 and 2024. She became a fellow of the American Academy of Nursing in 2020.

“I’m honored to join Chamberlain University’s Board of Trustees and share my passion and dedication for the nursing community and healthcare industry,” said Kingston. “Chamberlain’s commitment to increasing access to nursing education and its unwavering support for its students is truly inspiring, and I’m excited for the opportunity to make an impactful contribution to this institution.”

Kingston earned her bachelor’s degree in nursing from West Chester University in Pennsylvania and her master’s degree in nursing from the University of Pennsylvania. Kingston has a PhD in health policy from the University of the Sciences in Philadelphia.

About Chamberlain University

Chamberlain University, an Adtalem Global Education (NYSE: ATGE) institution, educates, empowers, and emboldens a diverse community of healthcare professionals who seek to advance the health of people, families, communities, and nations. Chamberlain has the largest school of nursing in the U.S., with both on-campus and online degree programs. Chamberlain is comprised of the College of Nursing and the College of Health Professions, offering a variety of bachelor’s, master’s, doctoral, and certificate programs. Chamberlain University is accredited by the Higher Learning Commission. Visit Chamberlain.edu for more information, and follow on Twitter, Instagram, Facebook, and LinkedIn.

About Adtalem Global Education

Adtalem Global Education is the leading provider of healthcare education in the U.S., shaping the future of healthcare by preparing a diverse workforce with high-quality academic programs. We innovate education pathways, align with industry needs and empower individuals to reach their full potential. Our commitment to excellence and inclusivity is reflected in our expansive network of institutions, serving over 90,000 students and supported by a strong community of approximately 350,000 alumni and nearly 10,000 dedicated employees. Visit Adtalem.com for more information and follow us on LinkedIn, Instagram and Facebook.

¹ Chamberlain University is the largest nursing school in the U.S.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250319393481/en/

Media Contact:

Talisha Holmes

872-213-6581

[email protected]

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Nursing Education Health Other Health Other Education University

MEDIA:

Logo

Fifth Third Secured Card Broadens Economic Access for 48,000+ Customers, And Counting

Graduates of Secured Card Program Upgrade to Unlimited 1.67% Cash Back on Purchases and No Annual Fee

CINCINNATI–(BUSINESS WIRE)–
Today, Fifth Third (NASDAQ: FITB) graduated another 3,900 customers through its Fifth Third Secured Card program, which has now helped more than 48,000 customers boost their credit scores and bolster their financial stability since its inception in 2019. Fifth Third Secured Card graduates automatically upgrade to the Bank’s flagship 1.67% Cash/Back Card, earning unlimited 1.67% cash back on purchases with no annual fee, while enjoying a lower purchase APR.

Fifth Third’s Secured Card program is designed to help customers who want to build or repair credit establish a positive credit history. Building and maintaining good credit can unlock many benefits for future borrowing, like qualifying for lower interest rates on mortgages and auto loans.

This spring’s graduates are leaving the program with improved credit and the potential for broader financial access:

• Customers who entered the program with no FICO score had an average FICO score of 729 at graduation.
• Customers who entered the program with a credit score increased their FICO score from 627 to 721 on average at graduation.
• More than 50% of the graduates are receiving a credit limit increase.

“Establishing good credit is a crucial step towards financial stability,” said Heather Chu, Head of Credit Card & Personal Lending Product at Fifth Third. “Whether you’re opening your first credit card or rebuilding your credit, Fifth Third’s Secured Card can help you create a positive credit history. Today’s graduates have built a strong foundation that can ultimately support long-term wealth and financial wellness.”

This year, Fifth Third’s Secured Card program is accelerating from bi-annual to quarterly cycles and anticipates graduating more than 17,000 customers. Customers graduate from Fifth Third’s Secured Card program after meeting key credit criteria like establishing a history of on-time payments over a period of 12 months. Upon graduation, customers are automatically given a 1.67% Cash/Back Card account, and any existing balance is transferred to the new account. The hold on the security deposit funding the Secured Card credit limit is then released, making that money available to the customer.

About Fifth Third

Fifth Third is a bank that’s as long on innovation as it is on history. Since 1858, we’ve been helping individuals, families, businesses and communities grow through smart financial services that improve lives. Our list of firsts is extensive, and it’s one that continues to expand as we explore the intersection of tech-driven innovation, dedicated people and focused community impact. Fifth Third is one of the few U.S.-based banks to have been named among Ethisphere’s World’s Most Ethical Companies^® for several years. With a commitment to taking care of our customers, employees, communities and shareholders, our goal is not only to be the nation’s highest performing regional bank, but to be the bank people most value and trust.

Fifth Third Bank, National Association is a federally chartered institution. Fifth Third Bancorp is the indirect parent company of Fifth Third Bank and its common stock is traded on the NASDAQ^® Global Select Market under the symbol “FITB.” Investor information and press releases can be viewed at www.53.com. Deposit and credit products provided by Fifth Third Bank, National Association. Member FDIC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250319302191/en/

Sophie Isherwood (Media Relations)

[email protected]

Matt Curoe (Investor Relations)

[email protected] | 513-534-2345

KEYWORDS: United States North America Ohio

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo

Agilent Research Catalyst Award Presented to Columbia University for Professor Pawel Muranski

Scientist recognized for pioneering advances in bioprocess development and biomanufacturing

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced that Columbia University has received an Agilent Research Catalyst (ARC) Award on behalf of Dr. Pawel Muranski, an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy.

Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irving Comprehensive Cancer Center. The award acknowledges Dr. Muranski’s ongoing efforts to develop live-cell analytical assays and workflows for bioprocess development and biomanufacturing of cell therapeutics under the current Good Manufacturing Practice (cGMP) guidelines and regulations.

Dr. Muranski’s research at Columbia University focuses on developing, validating, and implementing a novel, universally applicable cGMP platform for highly efficient ex vivo generation of clinical-grade multi-specific CD4⁺ cytotoxic T cells, which will be used to treat hematological malignancies (i.e., leukemias and lymphomas) and certain cancers (e.g., head and neck, melanoma, GI tract cancers) that frequently express tumor-associated antigens such as cancer-testis antigens, viral oncoproteins, and neoantigens resulting from so-called hot-spot mutations. The ARC award provides research funding and a suite of Agilent instruments and software including, a Seahorse XF Pro Analyzer, an xCELLigence Real-Time Cell Analysis (RTCA) MP instrument, a NovoCyte Penteon Flow Cytometer, a BioTek Cytation 1 Cell Imaging Multimode Reader, and a BioTek 800 TS Absorbance Reader.

“Cellular immunotherapy has transformed modern oncology, offering the potential for fully curative cancer treatments. However, given the personalized and labor-intensive nature of cellular therapies, significant challenges remain to fully achieve this goal,” stated Dr. Muranski. “We are excited to leverage advanced technologies and solutions from Agilent to enhance, streamline, and automate these therapies. Initially, we will use these tools to accelerate the development of innovative manufacturing methods. Subsequently, we will apply the same solutions to establish robust, standardized quality control assays essential for the routine production of anti-cancer T cells for patients in our clinical trials. We are very grateful to Agilent for supporting our work at Columbia.”

“Agilent is committed to expanding the frontiers of bioprocess development and biomanufacturing for advanced therapies. We are thrilled to present this ARC Award to Columbia University and Dr. Muranski,” added Xiaobo Wang, vice president and general manager of the Cell Function and Phenotyping Business at Agilent. “His pioneering work in developing live-cell analytical assays and GMP workflows is truly transformative and aligns perfectly with our mission to support cutting-edge research that drives innovation in cell therapeutics.”

“Dr. Muranski’s innovative approach to developing a cGMP platform for generating clinical-grade multi-specific CD4+ cytotoxic T cells is a significant leap forward in the field of cell therapeutics,” added Xavier Amouretti, vice president and general manager of the BioTek product line at Agilent. “By providing advanced analytical tools and resources, we aim to empower researchers like Dr. Muranski to push the boundaries of science and accelerate the development of transformative therapies for patients worldwide.”

The ARC Award program is committed to fostering scientific advancement and supporting noteworthy university research in life sciences, diagnostics, and chemical analysis by providing financial aid, products, and expertise. For more information, visit the Agilent Research Catalyst (ARC) program web page.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250319344447/en/

Media Contact

Naomi Goumillout

Agilent Technologies

+1.978.314.1862

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Science Software Biotechnology Research Oncology Health Health Technology Technology

MEDIA:

Logo

Orthofix Receives 510(k) Clearance and CE Mark for TrueLok Elevate Transverse Bone Transport System

LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and the European CE Mark for the TrueLok^™ Elevate Transverse Bone Transport (TBT) System.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250319068728/en/

TrueLok Elevate provides a limb preservation treatment option for addressing bony or soft tissue deformities and defects such as diabetic foot ulcers and nonhealing or deep tissue wounds. While the TBT procedure has previously been reported,¹ TrueLok Elevate is the first dedicated system for TBT to receive FDA clearance. The product is currently available in a limited market release in the U.S. and select international markets.

“Transverse bone transport with TrueLok Elevate now enables surgeons to effectively address challenging conditions in a patient’s extremity by allowing for an efficient and reproducible method to create a bone segment in the tibia that can then be gradually distracted over a period of several days,” said Dr. Emmy Oji, a podiatric foot and ankle surgeon at Valley Foot and Ankle Specialty Providers, who was among the first surgeons to apply the TrueLok Elevate system to a patient. “Clinical publications have shown this approach improves blood circulation to the affected limb and promotes wound healing in diabetic foot, potentially reducing the need for amputation.” Additionally, first patient cases in Europe were performed in the UK and Germany.

According to the American Diabetes Association, over 160,000 amputations occur per year in the U.S. as a result of diabetic-related complications, representing a sizable market opportunity of approximately $1.2 billion. In addition, published studies have shown that patients with diabetic foot ulcers who receive an amputation have a five-year mortality rate of 57% and are burdened with lifetime healthcare costs of just over $640,000 for care directly related to their amputation.^2,3 Therefore, TrueLok Elevate offers the potential to not only be a limb and cost-saving device, but most importantly, a life-saving solution to a challenging patient population.

“The introduction of the TrueLok Elevate system is a pivotal milestone in demonstrating our commitment to leading growth in the limb reconstruction market,” said Patrick Fisher, President of Global Orthopedics for Orthofix. “Within our orthopedics business, we are focusing on providing innovative solutions that spans four pillars: Limb Preservation, Extremity Deformity Correction, Limb Lengthening, and Complex Fracture Management to aid surgeons in managing patients with complex limb reconstruction needs.”

Those attending the American College of Foot & Ankle Surgeons (ACFAS) Annual Scientific Conference in Phoenix, AZ from March 27-30 can learn more about the TrueLok Elevate System by visiting booth 1045.

The TrueLok Elevate system represents the latest addition to Orthofix’s flagship product line, the TrueLok family of multiplanar external fixators, including the TrueLok EVO and TL-HEX^™ ring fixation systems. For indications, contraindications, warnings, precautions, potential adverse effects, and patient counseling information see the Instructions for Use or contact your local representative. Additional information about Orthofix’s full line of orthopedic solutions is available on Orthofix.com.

References:

1. Chen, Yan et al. “Effect of tibial cortex transverse transport in patients with recalcitrant diabetic foot ulcers: A prospective multicenter cohort study.” Journal of orthopaedic translation vol. 36 194-204. 12 Oct. 2022, doi:10.1016/j.jot.2022.09.002

2. Vuorlaakso, Miska et al. “Major Amputation Profoundly Increases Mortality in Patients With Diabetic Foot Infection.” Frontiers in surgery vol. 8 655902. 30 Apr. 2021, doi:10.3389/fsurg.2021.655902

3. Palli, S et al. “Impact of a limb salvage program on the economic burden of amputation in the United States.” Value in health vol. 19 Issue 3, A45

About Orthofix

Orthofix is a global medical technology company headquartered in Lewisville, Texas. By providing medical technologies that heal musculoskeletal pathologies, we deliver exceptional experiences and life-changing solutions to patients around the world. Orthofix offers a comprehensive portfolio of spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including the 7D FLASH™ Navigation System. To learn more, visit Orthofix.com and follow Orthofix on LinkedIn.

Forward-Looking Statements

This news release may include forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” “continue” or other comparable terminology. Orthofix cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Each forward-looking statement contained in this news release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: the ability of newly launched products to perform as designed and intended and to meet the needs of surgeons and patients, including as a result of the lack of robust clinical validation; and the risks identified under the heading “Risk Factors” in Orthofix Medical Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K filed with the SEC. The Company’s public filings with the SEC are available at www.sec.gov. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Orthofix does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250319068728/en/

Investors and Media

Julie Dewey, IRC

Chief Investor Relations & Communications Officer

[email protected]

209.613.6945

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Health FDA Medical Devices Diabetes Health Technology General Health Biotechnology

MEDIA:

Photo

TrueLok™ Elevate Transverse Bone Transport (TBT) System

Logo

Virpax Pharmaceuticals Announces Reverse Stock Split

BERWYN, Pa.–(BUSINESS WIRE)–
Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “VRPX” and will begin trading on a split-adjusted basis when the Nasdaq opens on March 21, 2025 (“Effective Time”). The new CUSIP number for the Common Stock following the reverse split will be 928251305.

At a special meeting of stockholders held on January 15, 2025 (the “Special Meeting”), the Company’s stockholders granted the Company’s Board of Directors (the “Board”) the discretion to effect a reverse stock split of the Company’s Common Stock at a ratio of not less than 1-for-2 and not more than 1-for-240, with such ratio to be determined by the Board. Following the Special Meeting, the final ratio of 1-for-25 was recently approved by the Board.

The 1-for-25 reverse stock split will proportionally reduce the number of outstanding shares of Common Stock from approximately 31,062,581 shares to approximately 1,242,504 shares and the ownership percentage of each shareholder will remain unchanged other than as a result of fractional shares. Proportional adjustments will be made to the number of shares of Common Stock issuable upon exercise or conversion of the Company’s outstanding equity awards and warrants, as well as the applicable exercise price. There will be no change to the total number of authorized shares of Common Stock as set forth in the Amended and Restated Certificate of Incorporation of the Company. Stockholders whose shares are held in brokerage accounts should direct any questions concerning the reverse stock split to their broker. All stockholders of record, whose shares are held with the Company’s transfer agent, VStock Transfer, may direct questions to VStock Transfer at (212) 828-8436 or [email protected].

The reverse split is intended to bring the Company into compliance with the minimum bid price requirement for maintaining the listing of its Common Stock on the Nasdaq Capital Market, and to make the bid price more attractive to a broader group of institutional and retail investors. The Nasdaq Capital Market requires, among other things, that a listed company’s common stock maintain a minimum bid price of at least $1.00 per share.

The Company’s transfer agent, VStock Transfer, LLC, which is also acting as the paying agent for the reverse split, will provide instructions to stockholders regarding the process for exchanging stock certificates. Any person who would otherwise be entitled to a fractional share of Common Stock as a result of the reclassification and combination following the Effective Time (after taking into account all fractional shares of Common Stock otherwise issuable to such holder) shall be entitled to receive a cash payment equal to the number of shares of the Common Stock held by such stockholder before the reverse split that would otherwise have been exchanged for such fractional share interest multiplied by the average closing sales price of the Common Stock as reported on the Nasdaq for the ten days preceding the Effective Time.

About Virpax Pharmaceuticals

Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta™ is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop one other prescription product candidate, NobrXiol™, which is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax has competitive cooperative research and development agreements (CRADAs) for two of its prescription drug candidates, one with the National Institutes of Health (NIH) and one with the Department of Defense (DOD). Virpax is also seeking partners for two nonprescription product candidates: AnQlar, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm™, which is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis. For more information, please visit https://www.virpaxpharma.com and follow us on Twitter, LinkedIn and YouTube.

Forward-Looking Statements

This press release contains certain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including those described below. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors, including the additional capital which will be necessary to complete studies and clinical trials that the Company plans to initiate and other factors listed under “Risk Factors” in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that the Company has filed with the U.S. Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250319664490/en/

Investor Contact:

[email protected]

KEYWORDS: United States North America Pennsylvania

INDUSTRY KEYWORDS: Research Medical Devices Infectious Diseases Hospitals Clinical Trials Biotechnology Health Pharmaceutical Science

MEDIA:

Posted on March 19, 2025 7:55 am

Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day

PR Newswire

• Provides long-term outlook beyond 2025: Revenues expected to grow at 4-5% compound annual growth rate (CAGR); adjusted diluted earnings per share (EPS) expected to grow at 7-9% CAGR
• Reaffirms guidance for full year 2025

SECAUCUS, N.J.
, March 19, 2025 /PRNewswire/ — At a meeting with analysts and investors at its 2025 Investor Day, members of the leadership team of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will discuss the company’s strategies to drive sustainable growth and deliver long-term shareholder value.   

“We are confident in Quest’s ability to grow at above-market rates in our core physician and hospital channels driven by increased market access, double-digit growth in advanced diagnostics across five key clinical areas, and the contributions of strategic partnerships and acquisitions,” said Jim Davis, Chairman, CEO and President. “We expect our continuous improvement initiatives – including investments in automation, robotics, and AI – to strengthen quality, customer and employee experiences, and productivity. Further, our new Project Nova IT initiative will modernize our systems architecture and lower IT costs over the long-term. These factors are reflected in the long-term outlook we are articulating today, which anticipates revenue growth at a 4-5% CAGR and adjusted EPS growth at a 7-9% CAGR beyond 2025.”

At the meeting, members of the company’s leadership team will highlight a range of strategic initiatives that are underway, including:

• Driving growth in the physician channel by delivering comprehensive diagnostic innovation, capitalizing on expanded health plan network access, extending geographic reach, and becoming a partner of choice for large enterprise customers.
• Growing in the hospital channel by serving hospitals through scaled and specialized reference testing, extending its range of collaborative lab solutions (“CoLab” previously Professional Laboratory Services) for helping hospitals manage their labs, and expanding in new geographies through accretive hospital lab outreach acquisitions.
• Expanding the company’s presence in high-growth areas by driving continued growth in demand for questhealth.com consumer-initiated testing, supporting life science partners with testing and services, and delivering insights through data analytics.
• Generating double-digit growth from advanced diagnostics tests with a focus on five key clinical areas: oncology (including for the company’s innovative Haystack MRD^™ minimal residual disease test for early cancer recurrence), advanced cardiometabolic health, women’s and reproductive health, brain health (featuring the company’s AD-Detect^™ blood-based Alzheimer’s disease testing services), and autoimmune disorders.
• Delivering 3% annual productivity and cost savings through the company’s Invigorate initiative, which focuses on fostering engaged employees, leaning out processes, and deploying technology to improve quality, productivity, and customer and employee experiences.
• Modernizing the company’s IT systems architectures through Project Nova, which will enhance customer and employee experiences, reduce IT costs and improve productivity across order to cash processes.
• Maintaining a disciplined capital deployment strategy that returns the majority of free cash flow to shareholders and drives growth through strategic investments and acquisitions.

Guidance for Full Year 2025     
The company today reaffirmed its guidance for full year 2025, as per the table below. For the first quarter of 2025, the company now expects that worse-than-anticipated weather during the period will create a headwind to revenue of approximately $25 million and to EPS of approximately $0.10.

	Low		High
Net revenues	$10.70 billion		$10.85 billion
Net revenues increase	8.4 %		9.9 %
Reported diluted EPS	$8.34		$8.59
Adjusted diluted EPS	$9.55		$9.80
Cash provided by operations	Approximately $1.45 billion
Capital expenditures	Approximately $500 million